VLTO enters its May 13 Q1 2026 earnings call with the Street in a broadly cautious but not alarmed mood — and the data in the lending and options markets tells a similar story.
The borrow market is about as relaxed as it gets for a stock approaching a catalyst. Availability remains extremely loose, with the lending pool barely touched at current short interest levels. Cost to borrow has drifted lower over the past month, now running at just 0.41% — well down from peaks above 0.7% seen in late April. Short interest itself is modest at 1.5% of the free float, with days to cover under 0.4. Options positioning reinforces the low-anxiety read: the put/call ratio of 0.09 is essentially flat with its 20-day average of 0.093, carrying a z-score near zero. There is no evidence of meaningful pre-earnings hedging in either the borrow or derivatives markets. The ORTEX short score of 29.5 is low and largely unchanged over the past two weeks, placing VLTO far from any crowded-short territory.
The analyst debate heading into the print is less about direction and more about degree. The consensus mean target of $108.41 implies roughly 25% upside from the current $86.84 close — a gap that reflects the stock's 13% YTD decline rather than sudden analyst enthusiasm. The recent cluster of activity around the April 29–30 earnings tells the story: Barclays trimmed its target to $113 from $117 while holding Overweight, and Citigroup nudged down to $102 from $104 while staying Neutral. UBS was the outlier, edging its target up a dollar to $101, also at Neutral. The pattern is mixed but not bearish — buy-rated analysts are cutting numbers to match reality, not abandoning the stock. The bull case centres on organic revenue momentum (5.1% year-over-year growth), operating leverage, and the sticky recurring-revenue base in consumables and services. Bears point to the 10-basis-point margin compression seen in the most recent quarter, macro sensitivity in water-quality end markets, and a valuation that, while at a 4% discount to peers on some metrics, still prices in a recovery the company must now demonstrate.
T. Rowe Price stands out on the institutional side, adding 1.07 million shares as of March 31 — the largest recent position change among top holders. Vanguard and BlackRock are steady. Insider activity, by contrast, has run one-directional: multiple senior executives sold shares in late February, though at prices above $93, the transactions look more like scheduled programme selling than a directional signal on the upcoming print.
The May 13 report is effectively a referendum on whether Veralto's organic growth trajectory can hold up against a weaker macro backdrop, and whether the operating margin stabilisation management has guided for is materialising in Q1 numbers.
See the live data behind this article on ORTEX.
Open VLTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
